Answers are grounded in this paper and cite their sources.
Introduction: AKI is associated with substantial morbidity and mortality, yet early diagnosis remains challenging because serum creatinine is a delayed marker of kidney dysfunction. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) has emerged as a promising biomarker of structural kidney injury. This study evaluated the diagnostic and prognostic utility of uNGAL in hospitalized adults with AKI. Study Design: Prospective diagnostic cohort study with 90-day follow-up. Methods Adults admitted between June and December 2024 were prospectively enrolled. The cohort included 215 patients with AKI defined according to KDIGO criteria and 173 hospitalized controls without AKI. u-NGAL was measured at enrollment using the Abbott Alinity i Urine NGAL assay. Receiver operating characteristic (ROC) analyses were performed to evaluate diagnostic performance for AKI detection and severity stratification. AKI patients were followed for renal recovery and hemodialysis initiation. Results A total of 388 participants were included. For AKI detection, uNGAL demonstrated moderate diagnostic accuracy with an area under the ROC curve (AUC) of 0.736 (p = 0.001). At a cutoff of 90.2 ng/mL, sensitivity was 56.7% and specificity was 80.3%. Diagnostic performance improved with AKI severity, with AUCs of 0.696 for stage 1 AKI and 0.785 for stage 3 AKI. At a cutoff of > 158.9 ng/mL, uNGAL achieved 87.5% sensitivity and 95.8% negative predictive value for identifying stage 3 AKI. Higher uNGAL concentrations were associated with hemodialysis initiation in unadjusted analyses but not after multivariable adjustment. No significant association was observed between uNGAL and renal recovery. Conclusions uNGAL demonstrated moderate diagnostic accuracy for AKI detection and good performance for identifying severe AKI. Although not independently associated with renal recovery or hemodialysis initiation, its ability to detect structural kidney injury and stratify AKI severity supports its role as a complementary biomarker alongside conventional measures of kidney function.
No takes yet. Share an insight, caveat, or question.
Jawabreh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: